Contact Us
Drug Search Results
More Filters [+]

Limaprost

Alternative Names: limaprost
Latest Update: 2024-04-10
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: EP1 Analogue

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Egypt | Korea | Taiwan

Approved Indications: None

Known Adverse Events: None

Company: Sino Biopharmaceutical
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Limaprost

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Spinal Stenosis|Intermittent Claudication

Phase 3: Bone Marrow Diseases|Spinal Diseases|Spinal Cord Diseases

Phase 2: Carpal Tunnel Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ChiCTR2300076153

N/A

Not yet recruiting

Spinal Stenosis

2026-06-30

ChiCTR2400092866

N/A

Recruiting

Spinal Stenosis

2026-04-30

LIMA_001

P3

Completed

Spinal Cord Diseases|Spinal Diseases|Bone Marrow Diseases

2022-10-01

ChiCTR1900028034

N/A

Not yet recruiting

Healthy Volunteers

2020-06-30

Recent News Events

Date

Type

Title

04/10/2024

PubMed

 Comparative Study on the Efficacy of Pregabalin Versus Limaprost in Patients With Lumbar Spinal Stenosis: A Prospective, Randomized Controlled Trial.

12/01/2023

PubMed

 Limaprost and the Risk of Bleeding: A Self-Controlled Case Series Study.

04/01/2023

PubMed

 Clinical Efficacy of Neurotropin for Lumbar Spinal Stenosis with Low Back Pain.

04/22/2021

News Article

 Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Samil for the Republic of Korea

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions